Proposed LCD - Molecular Pathology Procedures (DL35000)

BibliographyNCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia Version 3.2018. 2018.NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia Version 1.2018. 2018.NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms Version 2.2018. 2018.NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes Version 2.2018. 2018.NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers NCCN V1.2018. 2018.NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas Version 3.2018. 2018.NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia Version 1.2018. 2018.MacDermott RP. 6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in patients with inflammatory bowel disease. 2017.UpToDateWyles DL. Predictors of response to antiviral therapy for chronic hepatitis C virus infection.UpToDateReconsideration Request-CPT Code 0007M March 2017Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, Kwekkeboom DJ, Krenning EP, Baum RP, Paganelli G. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors.EJNMMI. 2016;43:839-851.Pavel M, Jann H, Prasad V, Drozdov I, Modlin IM, Kidd M. NET blood transcript analysis defines the crossing of the clinical Rubicon: when stable disease becomes progressive.Neuroendocrinology. 2017;104:180-182.Modlin IM, Frilling AF, Salem RR, Alaimo D, Drymousis P, Wasan HS, Callahan S, Faiz O, Weng L, Teixeira NS, Bodei L, Drozdov I, Kidd M. Blood measurements of neuroendocrine gene transcripts defines the effectiveness of surgical resection and ablation strategies.Surgery.2016;159:336-347.Cwikla JB, Bodei L, Cwikla A, Sankowski A, Alaimo D, Modlin IM, Kidd M. Gene Transcript analysis in advanced gastroenteropancreatic neuroendocrine tumors treated with somatostatin analogs defines stable and progressive disease.J Clin Endocrinol Metabolism. 2015;100:E1437-1445.Peczkowska M, Cwikla J, Kidd M, Lewczuk A, Kolasinska-Cwikla A, Niec D, Michalowska I, Prejbisz A, Januszewicz A, Chiarelli J, Bodei L, Modlin I. The clinical utility of circulating neuroendocrine gene transcript analysis in well-differentiated paragangliomas and pheochromocytomas.Eur J Endocrinol. 2017;176:143-157.Modlin IM, Drozdov I, Bodei L, Kidd M. Blood transcript analysis and metastatic recurrent small bowel carcinoid management. BMCCancer. 2014;14:564.Reconsideration Request- CPT Code 0007MJuly 2017Verbeek WH, Korse CM, Tesselaar ME. GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers.Eur J Endocrinol. 2016;174(1):R1-7.Oberg K, Modlin IM, De Herder W, et al. Consensus on biomarkers for neuroendocrine tumour disease.Lancet Oncol. 2015;16(9):e435-e446.Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors. NCT02948946.https://clinicaltrials.gov/ct2/show/study/NCT02948946Aetna Number: 0352. Tumor Markers.http://www.aetna.com/cpb/medical/data/300_399/0352.htmlReconsideration Request- IGH and TP53 October 20221. NCCN Biomarker Compendium , accessed October 20, 2022New LCD Request- Ceramides Risk Score- October 2022Mantovani A, Dugo C. Ceramides and risk of major adverse cardiovascular events: A meta-analysis of longitudinal studies.J Clin Lipidol. 2020;14(2):176-185. doi:10.1016/j.jacl.2020.01.005UpToDate accessed 4/5/2023Park LK, Garr Barry V, Hong J, Heebink J, Sah R, Peterson LR. Links between ceramides and cardiac function.Curr Opin Lipidol. 2022;33(1):47-56. doi:10.1097/MOL.0000000000000802Hilvo M, Vasile VC, Donato LJ, Hurme R, Laaksonen R. Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification.Front Endocrinol (Lausanne). 2020;11:570628. Published 2020 Sep 29. doi:10.3389/fendo.2020.570628Laaksonen R, Ekroos K, Sysi-Aho M, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.Eur Heart J. 2016;37(25):1967-1976. doi:10.1093/eurheartj/ehw148Havulinna AS, Sysi-Aho M, Hilvo M, et al. Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort.Arterioscler Thromb Vasc Biol. 2016;36(12):2424-2430. doi:10.1161/ATVBAHA.116.307497Meeusen JW, Donato LJ, Bryant SC, Baudhuin LM, Berger PB, Jaffe AS. Plasma Ceramides.Arterioscler Thromb Vasc Biol. 2018;38(8):1933-1939. doi:10.1161/ATVBAHA.118.311199Hilvo M, Vasile VC, Donato LJ, Hurme R, Laaksonen R. Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification.Front Endocrinol (Lausanne). 2020;11:570628. Published 2020 Sep 29. doi:10.3389/fendo.2020.570628Mantovani A, Dugo C. Ceramides and risk of major adverse cardiovascular events: A meta-analysis of longitudinal studies.J Clin Lipidol. 2020 Mar-Apr;14(2):176-185. doi: 10.1016/j.jacl.2020.01.005.Meeusen JW, Donato LJ, Kopecky SL, Vasile VC, Jaffe AS, Laaksonen R. Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors.Clin Chim Acta. 2020;511:138-142. doi:10.1016/j.cca.2020.10.005Vasile VC, Jaffe AS. An enhanced ceramide-based approach for primary prevention of atherosclerotic events.Eur Heart J Open. 2021;1(3):oeab016. Published 2021 Aug 12. doi:10.1093/ehjopen/oeab016Vasile VC, Meeusen JW, Medina Inojosa JR, et al. Ceramide Scores Predict Cardiovascular Risk in the Community.Arterioscler Thromb Vasc Biol. 2021;41(4):1558-1569. doi:10.1161/ATVBAHA.120.315530Akhiyat N, Vasile V, Ahmad A, et al. Plasma Ceramide Levels Are Elevated in Patients With Early Coronary Atherosclerosis and Endothelial Dysfunction.J Am Heart Assoc. 2022;11(7):e022852. doi:10.1161/JAHA.121.022852